跳至主要内容
临床试验/NCT00751751
NCT00751751已完成3 期

Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company0 个研究点目标入组 441 人开始时间: 2003年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
441
主要终点
Change in mean sitting diastolic blood pressure assessed by conventional BP measurements

研究概览

简要总结

To assess the efficacy of individually optimized doses of olmesartan medoxomil compared to losartan in elderly and very elderly patients with essential hypertension. The study hypothesis is non-inferiority of olmesartan medoxomil compared to losartan in lowering mean sitting diastolic blood pressure after 12 weeks of treatment compared to baseline. The study duration is up to 60 weeks, including a 52-week treatment period. After 12 weeks of treatment hydrochlorothiazide may be added to control blood pressure. Efficacy and safety measurements are carried out at up to 18 visits during the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 65 years or older
  • Mean sitting diastolic BP = 100-114 mmHg and mean sitting systolic BP >=150 mm HG

排除标准

  • Secondary hypertension
  • Malignant hypertension
  • Severe heart failure (NYHA III-IV)
  • History or evidence of renal disease
  • Recent history of myocardial infarction
  • Hypersensitivity to study drugs
  • History of drug or alcohol abuse

研究组 & 干预措施

1

Experimental

oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks

干预措施: olmesartan medoxomil + hydrochlorothiazide, if necessary (Drug)

2

Active Comparator

oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.

干预措施: losartan + hydrochlorothiazide, if necessary (Drug)

结局指标

主要结局

Change in mean sitting diastolic blood pressure assessed by conventional BP measurements

时间窗: 12 weeks

次要结局

  • Change in mean sitting diastolic BP assessed by conventional BP measurements(after 1, 2, 4, 8, 16, 20, 28, 36, 44, and 52 weeks)
  • Change in mean standing diastolic BP, mean sitting systolic BP and mean standing systolic BP(after 1, 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52 weeks)

研究者

发起方
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
申办方类型
Industry

相似试验

Olmesartan Medoxomil Versus Losartan in Elderly and... | 临床试验